JSA advised and assisted Lupin Limited in acquisition of portfolio of three hundred forty-three (343) brands (including all rights and interests associated with products) from Anglo French Drugs & Industries Limited (“AFDIL”) and its associates.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India offering branded and generic formulations, biotechnology products and active pharmaceutical ingredients. It holds a global leadership position in cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the antiinfective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas.

AFDIL is in the business of developing, manufacturing, marketing, and distribution of formulation of various drugs in the skin and respiratory segment. Deal value is of INR 325 crore. JSA team comprised of Shivpriya Nanda, Lead Partner; Zain Pandit, Partner; Gaurav G. Arora, Partner and Kshitij Gupta, Associate.